HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Gruvberger-Saal, S. K Articles by Hedenfalk, I. A Search for Related Content PubMed PubMed Citation Articles by Gruvberger-Saal, S. K Articles by Hedenfalk, I. A

¹ Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA
² Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
³ Joan and Sanford I. Weill Medical College, New York Presbyterian Hospital, Cornell University, New York, New York 10021, USA
⁴ Division of Oncology, Department of Clinical Sciences, Lund University, SE-221 85 Lund, Sweden

(Requests for offprints should be addressed to I A Hedenfalk; Email: ingrid.hedenfalk{at}med.lu.se)

Molecular profiling for classification and prognostic purposes has demonstrated that the genetic signatures of tumors contain information regarding biological properties as well as clinical behavior. This review highlights the progress that has been made in the field of gene expression profiling of human breast cancer. Breast cancer has become one of the most intensely studied human malignancies in the genomic era; several hundred papers over the last few years have investigated various clinical and biological aspects of human breast cancer using high-throughput molecular profiling techniques. Given the grossly heterogeneous nature of the disease and the lack of robust conventional markers for disease prediction, prognosis, and response to treatment, the notion that a transcriptional profile comprising multiple genes, rather than any single gene or other parameter, will be more predictive of tumor behavior is both appealing and reasonable. Promising results have emerged from these studies, correlating gene expression profiles with prognosis, recurrence, metastatic potential, therapeutic response, as well as biological and functional aspects of the disease. Clearly, the integration of genomic approaches into the clinic lies in the near future, but prospective studies based on larger patient cohorts representing the whole spectrum of breast cancer, oncogenic pathway-based studies, attendant care in bioinformatic analyses and validation studies are needed before the full promise of gene expression profiling can be realized in the clinical setting.

This article has been cited by other articles:

				S. J. Ramus, K. Elmasry, Z. Luo, A. Gammerman, K. Lu, A. Ayhan, N. Singh, W. G. McCluggage, I. J. Jacobs, J. C. Whittaker, et al. Predicting Clinical Outcome in Patients Diagnosed with Synchronous Ovarian and Endometrial Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5840 - 5848. [Abstract] [Full Text] [PDF]

				J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]